1

Matters of Administration

1.1

Welcome and apologies

1.2

Minutes and recommendations of the 166th MARC meeting

1.3

Declaration of potential conflicts of interest

2

Medsafe Pharmacovigilance Activities

2.1

Report on standing agenda items

2.2

Medsafe pharmacovigilance activities

2.3

Prescriber Update

2.4

Quarterly summary of recent safety communications

3

Pharmacovigilance Reports

3.1

Matters referred to the MARC under section 36 of the Medicines Act 1981

3.2

Matters referred to the MARC by Medsafe

3.2.1

Safety of metformin use in pregnancy

3.2.2

Fluconazole and use in pregnancy

3.2.3

National immunisation schedule change to Gardasil 9 as a 2 dose schedule for boys and girls

3.2.4

Hepatitis B reactivation with direct-acting antivirals for hepatitis C

4

Matters Arising from the NZ Pharmacovigilance Centre

4.1

CARM Quarterly Report

5

Other Business

5.1

Comments on sections 3 and 4 of the agenda

5.2

Therapeutic products regulation project – Update